Vosoritide (BMN-111; Voxzogo) is a peptide-based C-type natriuretic peptide (CNP) analogue approved in 2021 for the treatment of childhood achondroplasia. Vosoritide acts by binding to a receptor (target) called natriuretic peptide receptor type B (NPR-B), which reduces the activity of fibroblast growth factor receptor 3 (FGFR3). It is a peptide consisting of the amino acids proline and glycine plus the 37 C-terminal amino acids from natural human CNP. The complete peptide sequence is: PGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC.

纯度：≥98%

CAS：1480724-61-5